Drug
LU Ag13909
LU Ag13909: highest development phase Phase 2, developed by Lundbeck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AG13909 NCT06471829 | Phase 2 | Cushing's Disease |
| Lu AG13909 NCT05669950 | Phase 1/2 | Congenital Adrenal Hyperplasia |
Latest
No recent events.
Follow LU Ag13909 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.